[{"id":"1f17b25f-68c6-4567-8949-45ac3df1083a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04157517","created_at":"2021-01-18T20:16:52.449Z","updated_at":"2024-07-02T16:35:26.289Z","phase":"Phase 1/2","brief_title":"A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04157517","lead_sponsor":"Takeda","biomarkers":" BRAF • CTLA4","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • modakafusp alfa (TAK-573)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 12/12/2019","start_date":" 12/12/2019","primary_txt":" Primary completion: 11/04/2023","primary_completion_date":" 11/04/2023","study_txt":" Completion: 11/04/2023","study_completion_date":" 11/04/2023","last_update_posted":"2023-12-14"}]